MedPath

WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

WASHINGTON UNIVERSITY SCHOOL OF MEDICINE logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
1891-01-01
Employees
10K
Market Cap
-
Website
http://www.medschool.wustl.edu

Clinical Trials

1.7k

Active:106
Completed:946

Trial Phases

6 Phases

Early Phase 1:64
Phase 1:286
Phase 2:258
+3 more phases

Drug Approvals

2

FDA:2

Drug Approvals

Fludeoxyglucose F 18

Approval Date
Oct 29, 2021
FDA

Ammonia N 13

Approval Date
Oct 29, 2021
FDA

Clinical Trials

Distribution across different clinical trial phases (1403 trials with phase data)• Click on a phase to view related trials

Not Applicable
689 (49.1%)
Phase 1
286 (20.4%)
Phase 2
258 (18.4%)
Early Phase 1
64 (4.6%)
Phase 4
64 (4.6%)
Phase 3
42 (3.0%)

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Yescarta® (Axicabtagene Ciloleucel) or Post-Breyanzi® (Lisocabtagene Maraleucel) in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Not Applicable
Not yet recruiting
Conditions
Large B-cell Lymphoma
Interventions
First Posted Date
2025-07-04
Last Posted Date
2025-07-04
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
24
Registration Number
NCT07052305
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Advancing Biopsychosocial Care Training Initiative

Not Applicable
Recruiting
Conditions
Weight Management
Obesity Prevention
Obesity and Obesity-related Medical Conditions
Obesity and Overweight
Obesity
First Posted Date
2025-07-03
Last Posted Date
2025-07-11
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
6200
Registration Number
NCT07049861
Locations
🇺🇸

University of Missouri-Columbia, Columbia, Missouri, United States

🇺🇸

Children's Mercy Hospital Kansas City, Kansas City, Missouri, United States

🇺🇸

University of Missouri, Kansas City, Kansas City, Missouri, United States

and more 1 locations

Mindfulness to Enhance Cognitive Health in Latinx Older Adults

Not Applicable
Recruiting
Conditions
Mindfulness
Alzheimer's Disease Related Dementia
First Posted Date
2025-06-27
Last Posted Date
2025-06-27
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
60
Registration Number
NCT07040904
Locations
🇺🇸

Washington University, Saint Louis, Missouri, United States

Asciminib With or Without Sildenafil for Brain Tumors

Phase 1
Not yet recruiting
Conditions
Brain Tumor
Interventions
Procedure: Surgical resection or biopsy
First Posted Date
2025-06-26
Last Posted Date
2025-06-26
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
12
Registration Number
NCT07039760
Locations
🇺🇸

Washington University School of Medicine/St. Louis Children's Hospital, Saint Louis, Missouri, United States

Adapting, Implementing and Evaluating the Effectiveness of HARP for People With Disabilities

Not Applicable
Not yet recruiting
Conditions
Adults
Falls
Disabilities Physical
Fall Prevention
First Posted Date
2025-06-24
Last Posted Date
2025-07-01
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
80
Registration Number
NCT07033897
Locations
🇺🇸

Washington University in St. Louis, Saint Louis, Missouri, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 336
  • Next

News

Universal CAR-T Cell Therapy Achieves 91% Response Rate in Aggressive T Cell Cancers

An international Phase I/II trial of WU-CART-007, a universal CAR-T cell therapy, demonstrated a 91% overall response rate in patients with relapsed or refractory T cell acute lymphoblastic leukemia and T cell lymphoblastic lymphoma.

FDA-Approved Alzheimer's Drug Lecanemab Shows Manageable Safety Profile in Real-World Setting

WashU Medicine researchers found only 1% of Alzheimer's patients treated with lecanemab experienced severe side effects requiring hospitalization, confirming clinical trial safety data in a real-world setting.

Immunotherapy Breakthrough: Pembrolizumab Doubles Disease-Free Survival in Locally Advanced Head and Neck Cancer

An international Phase 3 trial shows pembrolizumab (Keytruda) added to standard therapy extends disease-free survival from 30 to 51.8 months in patients with locally advanced head and neck cancer.

Heavy Cannabis Use Linked to Triple Mortality Risk and Rising Psychosis Cases, Studies Find

People diagnosed with cannabis use disorder (CUD) face nearly triple the risk of death over five years compared to the general population, with a tenfold increase in suicide risk, according to a large Canadian study.

AI Advances in Breast Cancer Detection: New Technologies Show Promise for Earlier Diagnosis

AI technology developed at Washington University can analyze sequential mammograms to identify subtle tissue changes, predicting breast cancer risk 2.3 times more accurately than standard methods.

Nutrition's Critical Role in Cancer Care: From Prevention to Survivorship

Nutrition plays a vital role throughout the cancer journey, with different dietary strategies needed during active treatment versus survivorship and prevention phases.

Wren Laboratories Launches Advanced NETest 2.0 for Enhanced Neuroendocrine Tumor Diagnostics

Wren Laboratories has introduced NETest 2.0, an AI-enhanced liquid biopsy test featuring a 51-gene mRNA expression algorithm, achieving over 95% sensitivity in NET detection and 90% accuracy in identifying disease progression.

Early Leqembi Patient's Journey Highlights Promise and Limitations of New Alzheimer's Treatment

• One of the first U.S. patients to receive Leqembi (lecanemab) in 2020, Sue Bell's four-year treatment journey provides insights into the drug's real-world impact on Alzheimer's progression. • While Leqembi successfully clears beta-amyloid plaques and can slow disease progression, the $25,000-per-year treatment shows varying effectiveness among patients and does not restore lost cognitive function. • After four years of twice-monthly infusions, Sue Bell discontinued treatment as her condition progressed beyond the early stage where Leqembi provides optimal benefit.

Novel Approaches Transform Lymphoma Treatment Landscape: From Genomic Profiling to Liquid Biopsies

• Dr. David Russler-Germain highlights revolutionary shifts in lymphoma treatment, from traditional chemotherapy to targeted therapies including BTK inhibitors, CAR-T cells, and bispecific antibodies. • Groundbreaking research in follicular lymphoma genomic profiling reveals crucial mutations, advancing understanding of disease mechanisms and treatment approaches. • Circulating tumor DNA emerges as a promising non-invasive biomarker for real-time monitoring of lymphoma progression and treatment response.

New Analysis Shows Next-Gen Alzheimer's Drugs Add 8-10 Months of Independent Living

WashU Medicine researchers have translated clinical trial data for lecanemab and donanemab into practical terms, showing these drugs can extend independent living by up to 10 months for early-stage Alzheimer's patients.

© Copyright 2025. All Rights Reserved by MedPath